An Overview of Future Development Methods of Infectious Bronchitis Vaccines

Vaccines are major disease-controlling tools in human and animal practices. Vaccination controlled or even eradicated a long list of diseases worldwide. Classic viral vaccines are usually composed of live or inactivated whole viruses and have been produced for many years. However, they are unsuccessful, especially in persistent infections, fast-evolving viruses, complex and compound antigens, and emerging agents. Novel vaccine development technologies such as DNA, protein, or viral vector vaccines have revolutionized vaccine development and opened a new horizon for study and research in vaccine research and production vision. Newly-developed vaccines, or even most traditional ones, are based on new technologies, especially in human diseases where cost and complications in production can be ignored. However, in animal health, especially for commercial poultry production, the cost of development, simplicity, and mass application of large-scale production cannot be overlooked. In recent years, the significance of producing novel vaccines has been highlighted in parallel with technological advancement, especially with emerging novel variants of infectious bronchitis viruses—serious poultry pathogens for years. In this review, we will introduce some studies on novel vaccine development techniques and investigate the results of those vaccines in the protection of chickens and their clinical outcomes.